FDA Approves Sun Pharma's Fosphenytoin Sodium Injection
Posted on: Thursday, 20 March 2008, 09:01 CDT
Sun Pharmaceutical Industries has announced that the FDA has granted approval for the abbreviated new drug application to market fosphenytoin sodium injection.
Fosphenytoin sodium injection USP, 50mg PE/mL, is therapeutically equivalent to Parke Davis's Cerebyx, and is available in two packs: 100mg PE/ 2mL and 500mg PE/10mL single dose vials.
Fosphenytoin sodium is used for the control of generalized convulsive status epilepticus as well as for prevention and treatment of seizures occurring during neurosurgery. This product will reach the market shortly.
Source: Datamonitor
Related Articles
- Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
- Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
- Institute of Food Technologists: Slashing Sodium No Simple Answer to Hypertension
- Efficacy and Systemic Tolerability of Mometasone Furoate and Betamethasone Sodium Phosphate
- STADA Pharmaceuticals Extends Voucher Program for Rheumatrex(R) Dose Pack(TM) (Methotrexate Sodium Tablets)
- New Study Showed Investigational Medicine ARCOXIA Had Improved Gastrointestinal Tolerability Compared With Diclofenac Sodium
- A Sodium-Rich Carbonated Mineral Water Reduces Cardiovascular Risk in Postmenopausal Women1,2
- Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells
- Multimodality Noninvasive Imaging of Gene Transfer Using the Human Sodium Iodide Symporter
Rating: 2.3 / 5 (3 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds